Renal insufficiency and anemia are independent risk factors for death among patients with acute myocardial infarction1,21As published material, the contents of this manuscript may not be cited, quoted, reproduced or published without the consent of the authors.2The analyses upon which this publication is based were performed under Contract Number 500-96-P704, entitled “Operation Utilization and Quality Control Peer Review Organization (PRO) for the State of Georgia” and sponsored by the Centers for Medicare and Medicaid Services (CMS), Department of Health and Human Services. The conclusions and opinions expressed, and methods used herein are those of the authors. They do not necessarily reflect CMS policy. The authors assume full responsibility for the accuracy and completeness of the ideas presented. This article is a direct result of the Health Care Quality Improvement Program initiated by CMS, which has encouraged identification of quality improvement projects derived from analysis of patterns of care, and therefore required no special funding on the part of this Contractor. Ideas and contributions to the authors concerning experience in engaging with issues presented are welcomed.  by Langston, Robert D. et al.
Kidney International, Vol. 64 (2003), pp. 1398–1405
CLINICAL NEPHROLOGY–EPIDEMIOLOGY–CLINICAL TRIALS
Renal insufficiency and anemia are independent risk factors
for death among patients with acute myocardial infarction1,2
ROBERT D. LANGSTON, RODNEY PRESLEY, W. DANA FLANDERS, and WILLIAM M. MCCLELLAN
Georgia Medical Care Foundation, Atlanta, Georgia; Rollins School of Public Health, Emory University,
Atlanta, Georgia; and Division of Kidney Disease, Emory University, Atlanta, Georgia
Renal insufficiency and anemia are independent risk factors for
death among patients with acute myocardial infarction.
Background. Chronic kidney disease (CKD) increases risk
of death among patients with coronary artery disease. Mortality
risks associated with CKD among patients with cardiovascular
disease (CVD) are not well defined. Anemia is associated with
increased mortality in end-stage renal disease (ESRD) patients
and may also increase risk among patients with CVD.
Methods. A random sample of patients admitted to the hos-
pital in a single southern state with a principal diagnosis of acute
myocardial infarction (ICD-9 codes 410.xx) were followed up
after hospital discharge.
Results. CKD was found in 60% of the cohort. Hematocrit of
40 was found in 46% of the patients; 26.0% had a hematocrit
between 36% and 39%, 21.8% between 30% and 35%, and
5.9% had a hematocrit of less than 30%. The 1-year death rates
among individuals with and without CKD were 31.7% and
10.4% respectively [odds ratio (OR)  4.00 (2.34, 6.91)]. The
mortality at one year was 18.6% for individuals with a hemato-
crit greater than or equal to 40%; 23.5% (OR 1.35; 95% CI
0.78, 2.32) for hematocrit 36% to 39%; 30.7% (OR  1.94;
95% CI  1.12, 3.34) for hematocrit between 30% and 35%;
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and 35.8% (OR  3.16; 95% CI  1.35, 7.40) for those with
a hematocrit less than 30% (2 for trend was 12.2, P  0.007).
Both hematocrit and serum creatinine were independently as-
sociated with increased risk of death during follow-up after
controlling for other patient risk factors.
Conclusion. CKD and decreasing hematocrit were frequent
among older patients hospitalized for acute myocardial infarction
and are independent predictors of subsequent risk of death.
Chronic kidney disease (CKD) increases the risk of
death among individuals with coronary artery disease [1–7].
This increased risk has been observed among patients
with coronary artery disease following noncardiac and
cardiac surgery, coronary angioplasty, and acute myocar-
dial infarction [1–6]. CKD was associated with a 40%
increased risk of myocardial infarction, stroke and death
due to cardiovascular disease among participants in the
Heart Outcomes and Prevention Evaluation (HOPE)
study [7]. Finally, an association between renal insuffi-
ciency and risk of all-cause and cardiovascular disease
(CVD)-associated death has been reported in some
[8–10] but not all [11, 12] population-based studies.
The factors associated with CKD that might confer in-
creased risk of mortality on patients with CVD have not
been well defined. Anemia secondary to CKD is one possi-
ble means by which renal insufficiency might increase
the risk of death among patients with coronary artery
disease. Anemia is common among individuals with
CKD, particularly when the glomerular filtration rate
falls below 60 mL/min [13, 14]. Anemia in CKD patients
is associated with the occurrence and progression of left
ventricular hypertrophy and dilatation, which, in turn,
increases the risk of heart failure, arrhythmia, and death
[15]. Anemia may also increase the risk of death among
patients with ischemic heart disease. In a recent study,
treatment of anemia with transfusion was reported to
reduce the risk of death among anemic patients following
a myocardial infarction [16].
We have previously reported that elderly patients hos-
pitalized with congestive heart failure have a high preva-
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lence of both anemia and CKD and that these are inde-
pendent risk factors for subsequent mortality [17]. In
this report, we describe the joint role of anemia and
CKD as risk factors for mortality following an acute




This is a retrospective cohort study of randomly se-
lected patients discharged from community hospitals
with a primary diagnosis of acute myocardial infarction.
Study sample
All Medicare patients admitted to any general hospital
in a single southeastern state between July 1, 1998 and
December 31, 1998 and who were alive at discharge with
a principal diagnosis of acute myocardial infarction [ICD-9
code 410.xx of the International Classification of Dis-
eases, 9th Revision, Clinical Modification (ICD-9-CM)],
were eligible for inclusion in the study. We used the first
admission for patients with more than one admission dur-
ing the period. Records for eligible patients were identified
by the Medicare Medical Information System and a ran-
dom sample of eligible discharges was chosen. This ran-
dom sample represented approximately 15% of all Medi-
care acute myocardial infarction admissions in the state
during the entry period.
Data abstraction
Trained abstractors, blinded to the study hypothesis,
used a standardized form to abstract patient charts. Data
abstracted for each patient included date of admission
and discharge, demographic information (age, race, and
gender), and degree of mobility on discharge. Comorbid
conditions abstracted included a history of stroke, end-
stage renal disease (ESRD), myocardial infarction, heart
failure, diabetes, and hypertension. Patients given an
angiotensin-converting enzyme (ACE) inhibitor on dis-
charge were also identified.
Reports of left ventricular ejection fractions were
identified and recorded. If a previous and a current ejec-
tion fraction were both present in the record, we used
the lower value for the purposes of analysis. The pulse
rate, systolic and diastolic blood pressures, and the pres-
ence of peripheral edema on admission were recorded.
Radiographic changes of pulmonary edema or heart fail-
ure were recorded.
Variables were abstracted describing both mobility
and functional status at discharge. The Charlson comor-
bidity score for each patient was calculated using all of
the secondary diagnoses at the index admission [18].
Laboratory values for the first serum creatinine and he-
matocrit recorded in the chart were abstracted. We calcu-
lated a creatinine clearance for each patient according
to the Cockcroft-Gault equation [19]. We defined CKD
as a creatinine clearance 60 mL/min when we used the
calculated creatinine clearance as a categorical variable
in multivariable models.
We excluded from the study individuals with a serum
creatinine in excess of 6 mg/dL. We used the National
Kidney Foundation/Dialysis Outcomes Quality Initiative
(NKF-K/DOQI) guidelines for anemia to define gender-
independent anemia as a hematocrit of less than 30%
when hematocrit was included as a categorical variable
in multivariable models [20].
Follow-up
Follow-up for patients admitted between July 1, 1998
and December 31, 1998 began on the date of discharge
from the hospital for the index admission and continued
until March 1, 2001. Patients were characterized as dead
if a date of death had been recorded for them during
the follow-up period in the Medicare Enrollment Data-
base and as missing if neither a date of death nor a
current Medicare eligibility record was found. We were
unable to identify either a death date or evidence for
current eligibility for 12 (1.9%) of the patients and these
patients were excluded from mortality analyses.
Analysis
We calculated descriptive statistics and the 12-month
risk of death for selected categories of key covariates. We
used risk ratios and associated confidence intervals to
measure the association between categorical variables and
risk of death. We used Kaplan–Meier survival curves to
examine the survival associated with anemia and CKD.
Using an a priori selection of risk factors, we used a
Cox regression model to account for confounding and
to assess the joint effects of renal insufficiency and ane-
mia. In the reported model, we used creatinine clearance
and hematocrit as continuous variables along with age,
ejection fraction, and indicators for gender, race, comor-
bid history (stroke, congestive heart failure), hyperten-
sion, diabetes mellitus, a previous history of myocardial
infarction, and discharge functional status. We assessed
the proportional hazard assumption using plots of log-log
survival, and interaction terms with time. We screened
for potential collinearity using correlation coefficients.
We further assessed model fit by including interaction
terms between creatinine clearance and hematocrit. All
analyses were conducted using SAS Version 8.12, SAS
Institute, Cary, North Carolina.
We assessed the sensitivity of our results to model speci-
fication by examining a multivariate model where we
treated creatinine clearance (CKD yes/no) and hemato-
crit (anemia yes/no) as dichotomous variables. We also
examined a model similar to the reported model but ex-
cluding hematocrit, and another model in which we substi-
tuted creatinine for creatinine clearance. A model was
also examined in which we excluded ejection fraction.
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Table 1. Characteristics of hematocrit levels
Hematocrit
40% 36–39% 30–35% 30%
Number 242 (46%) 136 (26%) 114 (22%) 31 (6%)
Mean (SD) hematocrita 44.1% (3.0) 37.9% (1.1) 33.3% (1.7) 25.1% (3.5)
Chronic kidney diseasea 48% 64% 75% 80%
Mean creatinine clearance (SD)a mL/min 67 (33) 56 (27) 45 (23) 48 (33)
% discharged on ACE inhibitor 33% 29% 37% 26%
One-year mortalityb 18.6% 23.5% 30.7% 41.9%
ACE inhibitor is angiotensin-converting enzyme inhibitor (P  0.4658).
a P  0.0001
b P  0.0067
RESULTS
Our sample included 709 patients admitted to commu-
nity hospitals with acute myocardial infarction. After
excluding duplicate records of patients with subsequent
admissions within the entry time period (N  63), pa-
tients with creatinine 6.0 (N  11), patients who died
prior to discharge (N  64), and patients lost to follow-
up (N  12), data from 559 patients were analyzed.
Records of patients from 101 hospitals were used in the
analysis, a mean (SD) of 5.5 (5.7) patients per hospital
and a 25th to 75th intraquartile range from two to seven
patients. The range of patients contributed to the sample
by an individual hospital was from 1 to 31.
The mean (SD) age of the cohort was 73.8 (10.0) years,
with a range from 32 to 97 years, 49% were female, and
82% were white. A history of prior myocardial infarction
was present for 35% of the patients. Hypertension was
reported for 71%, diabetes for 33%, and a history of a
previous stroke was reported for 19%. Heart failure was
reported as a preexisting condition for 23% of patients.
A report describing previous or current left ventricular
ejection fraction was found in 61.0% of the patients’
charts. The mean (SD) ejection fraction was 44.0% (14.2),
with a range from 10% to 94%. Among the 342 patients
with a recorded ejection fraction, 35% had left ventricu-
lar systolic dysfunction with a mean (SD) ejection frac-
tion of 28.6% (6.6). An ACE inhibitor was prescribed
at discharge for 33% of the cohort.
A serum creatinine value was reported on admission
for 529 (95%) of the cohort. The mean (SD) value was
1.35 (0.74) mg/dL, with a range from 0.2 to 6.0 mg/dL
and a 25th to 75th intraquartile range from 0.9 to 1.5
mg/dL. We were able to estimate the creatinine clearance
for 508 subjects. Patients with a creatinine clearance of
200 mL/min were excluded (N  1). The mean (SD)
clearance was 57(28) mL/min with a range from 4.6 to
170 mL/min and a 25th to 75th intraquartile range from
37 mL/min to 72 mL/min. CKD, defined by a creatinine
clearance of 60 mL/min or less, was present in 60% of the
cohort. Men (48.7%) were less likely than were women
(72.7%) to have CKD (OR 0.36; 95% CI 0.24, 0.53).
The mean (SD) serum creatinine among individuals with
CKD was 1.59 (0.85) mg/dL and among those without
CKD it was 1.01 (0.23) mg/dL (P  0.001). The mean
(SD) creatinine clearance among individuals with CKD
was 39.4 (13.3) mL/min and among those without CKD
it was 85.0 (22.6) mL/min (P  0.001).
A hematocrit was recorded for 523 (94%) of the co-
hort. The mean (SD) hematocrit was 39.0% (6.1), with
a 25th to 75th intraquartile range from 35.2% to 43.2%.
The proportion of patients with a hematocrit greater
than or equal to 40% was 46.3%; 26.0% had a hematocrit
between 36% and 39%, 21.8% between 30% and 35%
and 5.9% had a hematocrit of less than 30%. The propor-
tion of patients with CKD increased with decreasing
hematocrit (Table 1).
Among individuals with a hematocrit less than 30%,
80% had a creatinine clearance less than or equal to 60
mL/min, with a mean clearance for this level of hemato-
crit of 48 mL/min. Of note was that 58% of nonanemic
acute myocardial infarction patients (hematocrit30%)
had CKD and 20% of anemic patients (hematocrit
30%) had a creatinine clearance greater than 60 mL/
min (Table 1).
Mortality rates were high. Of the cohort, 37% (N 
205) died during follow-up and mortality at 1 year was
24.3%. The presence of CKD was associated with an
increased risk of death (Fig. 1). One-year mortality rates
for various risk factors are shown in Table 2. One-year
mortality rates among individuals with and without CKD
were 31.7% and 10.4%, respectively [odds ratio (OR) 
4.00 (2.34, 6.91) (P  0.0001)]. Anemia on admission to
the hospital was associated with an increased risk of
death (Table 1 and Fig. 2). Compared to individuals with
a hematocrit greater than or equal to 40%, the relative
risk (95% CI) for death for individuals with a hematocrit
between 36% and 39% was OR  1.35 (95% CI 0.78,
2.32); OR  1.94 (95% CI 1.12, 3.34) for a hematocrit
between 30% and 35%; and OR  3.16, (95% CI 1.35,
7.40) for a hematocrit less than 30% (2) for trend was
12.2 (P  0.007).
Both hematocrit and serum creatinine were indepen-
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Fig. 1. Kaplan-Meier survival curve for individuals with and without
creatinine clearance 60 mL/min.
Table 2. One-year mortality by risk factor
Number One-year
Characteristic (% of category) mortality OR (95% CI)
Age years
70 172 (31) 10.5% 1
71–75 127 (22) 18.9% 1.99 (0.98, 4.06)
76–80 114 (20) 27.2% 3.20 (1.61, 6.37)
80 146 (26) 43.2% 6.49 (3.48, 12.2)
Gender
Male 284 (51) 20.4% 1
Female 275 (49) 28.4% 1.54 (1.04, 2.28)
Race
African American 99 (18) 23.2% 1
White 454 (82) 24.7% 1.08 (0.65, 1.81)
Previous myocardial infarction 194 (35) 24.7% 1.03 (0.69, 1.55)
Comorbidity
Stroke 105 (19) 33.3% 1.74 (1.10, 2.77)
Congestive heart failure 130 (23) 47.7% 4.37 (2.86, 6.69)
High blood pressure 396 (71) 24.5% 1.03 (0.67, 1.58)
Diabetes 185 (33) 32.4% 1.88 (1.26, 2.80)
Functional status
Normal 208 (57) 16.8% 1
Moderate impairment 102 (28) 35.8% 2.70 (1.51, 4.82)
Severe impairment 52 (14) 38.5% 3.09 (1.51, 6.34)
Left ventricular function
Normal function 217 (39) 14.7% 1
Systolic dysfunction 118 (21) 36.4% 3.32 (1.90, 5.81)
Undetermined 224 (40) 27.7% 2.21 (1.34, 3.66)
Creatinine clearance mL/min
90 62 (12) 6.4% 1
61–90 139 (27) 12.2% 1.93 (0.68, 5.5)
30–60 231 (46) 22.1% 3.48 (1.31, 9.25)
30 75 (15) 61.3% 9.7 (3.7, 25.4)
dently associated with increased 1-year mortality during
follow-up (Table 3) after controlling for age, gender,
race, hypertension, diabetes, heart failure, a previous
myocardial infarction, lowest ejection fraction, discharge
functional status, Charlson comorbidity index, and status
of ACE inhibitor use at discharge. For each 1% increase
in hematocrit, the overall mortality declined 4% (P 
0.011), and for each 1 mL/min increase in creatinine
clearance, the mortality rate declined 2% (P  0.0019).
Fig. 2. Kaplan-Meier survival curve for individuals with hematocrit
levels of 30%, 30% to 35%, 36% to 39%, and 40%.
An interaction term for renal function and anemia was
not significant.
The association between anemia and subsequent risk
of mortality was robust with respect to model specifica-
tion. For example, hematocrit (P  0.005) and serum
creatinine (P 0.03) remained associated with increased
mortality when included as categorical variables. Fur-
ther, when hematocrit was excluded from models con-
taining serum creatinine, the hazard for serum creatinine
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Table 3. Results of Cox proportional hazard model
for 1-year mortality
Model
(hematocrit and creatinine clearance
as continuous variables) (N  485)
Risk factor Parameter Hazard ratio (95% CI)
Hematocrit % 0.04035 0.96 (0.93, 0.99)
Creatinine clearance mL/min 0.02455 0.98 (0.96, 0.99)
Age years 0.02842 1.03 (1.0, 1.06)
Female gender 0.38439 0.68 (0.45, 1.02)
White race 0.56583 1.76 (1.04, 2.99)
Comorbid conditions
Stroke 0.21361 1.28 (0.78, 1.96)
Myocardial infarction 0.13704 0.87 (0.57, 1.32)
Hypertension 0.20516 0.82 (0.53, 1.24)
Diabetes 0.67465 1.96 (1.31, 2.95)
Previous congestive heart
failure 0.55096 1.74 (1.13, 2.66)
Left ventricular function
Normal function — 1
Systolic dysfunction 0.7996 2.22 (1.34, 3.67)
Not determined 0.42441 1.53 (0.93, 2.50)
Functional status at discharge
Normal — 1
Moderate impairment 0.29097 1.34 (0.83, 2.15)
Severe impairment 0.25145 1.29 (0.70, 2.38)
Charlson score 0.03801 1.04 (1.00, 1.08)
ACE inhibitor at discharge 0.03464 1.04 (0.69, 1.56)
ACE inhibitor is angiotensin-converting enzyme inhibitor.
was stronger, consistent with confounding of the associa-
tion between serum creatinine and mortality by anemia.
When serum creatinine was substituted for creatinine
clearance, creatinine remained strongly associated with
mortality (P 0.006). Finally, when we excluded ejection
fraction, which had a large number of missing values,
our results were unchanged.
Figure 3 shows the proportion of patients who died
within groups created by the combination of the hemato-
crit levels 40%, 36% to 40%, 30% to 36%, and 30%
with the creatinine clearance levels 90 mL/min, 90 to
61 mL/min, 60 to 30 mL/min, and 30 mL/min. The risk
of death at 1 year varied widely among the different
hematocrit/renal function groups (P 0.0001). For most
hematocrit levels, the proportion of patients dying in-
creased with decreasing creatinine clearance and, for any
level of creatinine clearance, the risk of death increased
with decreasing hematocrit. The low death rates noted
for individuals with normal renal function (creatinine
clearance 90 mL/min) and a hematocrit less than 36%
are likely due to the very small numbers of individuals
in these two cells (N  2 for those with a hematocrit of
30% to 35% and N  3 for those with a hematocrit of
30%). The low death rate for individuals with a renal
function of creatinine clearance 60 to 90 mL/min and
hematocrit of 30% is also likely due to the small num-
ber in that cell (N  4).
Fig. 3. Proportion of patients dying within groups jointly defined by
level of hematocrit and creatinine clearance.
DISCUSSION
The main observation of our study is that decreased
hematocrit and CKD are both frequent among elderly
patients with a myocardial infarction admitted to com-
munity hospitals and are independently associated with
increased mortality following discharge. The risk associ-
ated with decreased hematocrit was strong and graded
and persisted after controlling for other factors, including
renal function, that might have contributed to increased
risk of death. Controlling for hematocrit weakened, but
did not eliminate the association between CKD and mor-
tality. These observations are important as they suggest
that anemia may be one way that CKD contributes to
increased risk of death among patients with ischemic
heart disease.
Previous studies have reported increased risk of death
among anemic patients with and without CKD. A study
of 1958 surgical patients found that uncorrected preoper-
ative anemia was associated with increased 30-day post-
operative mortality [21]. The mortality rate in this study
among individuals with a hemoglobin value between 9.0
and 9.9 g/dL was sixfold greater than for those individuals
with hemoglobin of 12 g/dL or greater. The association
between hemoglobin and risk of death was much stronger
among individuals with CVD and the risk of death for
individuals with CVD progressively increased for hemo-
globin of 10 g/dL or less when compared to the risk of
individuals free of CVD.
Holland and Lam [22] examined the risk factors for
hospitalization and death among a cohort of 362 patients
with advanced CKD. A hemoglobin of 9.5 g/dL or less
was present in 16.3% of these patients and was associated
with increased risk of hospitalization and death. After
controlling for other risk factors, the risk of hospitaliza-
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tion decreased 1.1% with each 1 g/dL increase in hemo-
globin. In contrast, no independent association between
hemoglobin and risk of death was found although the
number of deaths was small and the cohort may not have
had sufficient power to detect an association.
Wu et al [16] reported that anemic (hematocrit less
than 30%) Medicare beneficiaries who were admitted
with an acute myocardial infarction and received a trans-
fusion had reduced 30-day mortality. Renal insufficiency
was described as present or absent and was present in
11.4% of this cohort and increased in prevalence to 45%
in the most severely anemic patients. The protective
benefit of transfusion in these patients persisted after
adjustment for other risk factors for mortality, including
the presence of renal insufficiency.
Beattie et al [23] reported that, among patients with
CKD admitted for myocardial infarction, the mean he-
moglobin varied between 13.6 g/dL for individuals with
normal renal function and 12.7g/dL for those with a
creatinine clearance less than 46.2 mL/min/72 kg. They
found strong associations between the degree of renal
function and cardiac arrhythmia, asystole, pulmonary
edema, and conduction disturbances. Patients with in-
creasing degrees of renal insufficiency had increased risk
of death during subsequent follow-up, with 5-year mor-
tality rates in excess of 60% among individuals with
creatinine clearances less than 47 mL/min/72 kg com-
pared to less than 35% mortality among individuals with
higher levels of renal function. Further, in multivariate
analyses of their data, they found that both renal insuffi-
ciency and decreasing hemoglobin were independent risk
factors for subsequent mortality [24].
In contrast to these studies, Rigatto et al [25] found
no association between baseline hemoglobin level and
subsequent risk of ischemic heart disease among 638
posttransplant patients who were free of CVD 1-year
posttransplant and who were then followed for a median
of 7.2 years. These patients had a mean baseline hemo-
globin of 12.6 gm/dL. The risk of new congestive heart
failure, unlike incident ischemic heart disease, was strongly
associated with baseline hemoglobin level in both univar-
iate and multivariate analyses. These patients differed
from those we studied in that our patients had estab-
lished CVD at the onset of follow-up, suggesting that
anemia may be more strongly associated with the out-
come of established ischemic heart disease than with risk
of incident disease.
The association between hemoglobin level and in-
creased risk of CVD may not be entirely linear and there is
evidence of increased risk of death at higher hemoglobin
levels as well. The Puerto Rico Heart Study [26] reported
that among individuals with a hematocrit in excess of
49% had more than a twofold increase in risk of myocar-
dial infarction, coronary insufficiency, or death and that
this risk persisted after controlling for conventional risk
factors. Similar although inconsistent associations have
been reported from the Honolulu Heart Program [27, 28].
The observations from the above population-based stud-
ies are consistent with the increased mortality noted
among hemodialysis patients randomized to normaliza-
tion of hematocrit (target hematocrit value, 42%) when
compared to conventionally treated patients (target he-
matocrit value, 30%) in the Normal Hematocrit Trial
[29]. This trial randomly assigned hemodialysis patients
with advanced CVD to erythropoietin therapy that
would either maintain conventional or normal hemato-
crit levels. A clinically significant increase in risk of
death, hazard ratio 1.3 (95% CI 0.9, 1.9) was noted for
patients assigned to the intervention group after a 29
months of follow-up and the trial was halted.
The association between increased risk of death and
anemia following hospitalization for acute myocardial
infarction could reflect several factors. For example, ane-
mia might amplify hypoxia associated with intermittent
episodes of angina pectoris. Further, adaptation to
chronic anemia involves increases in heart rate, cardiac
index, and stroke work as well as expansion of plasma
volume [30, 31]. These hemodynamic compensations
may additionally stress left ventricular function in pa-
tients with heart failure [32, 33]. The hemodynamic ef-
fects of chronic and acute anemia have been observed
with hemoglobin in the range of 7 g/dL for patients
without hemoglobinopathy and below 10 g/dL for pa-
tients with sickle cell anemia [34]. These hemoglobin
levels are comparable to those we observed for individu-
als in our study with hematocrit values between 30%
and 35% (mean, 33.3%) and for those with a hematocrit
value less than 30% (mean, 25.1%).
Anemia is associated with changes in left ventricular
anatomy among patients with CKD and it is possible that
these changes could contribute to worsening left ventricular
diastolic and/or systolic dysfunction and consequent in-
creased risk of death. For example, Tucker et al [35] found
an independent association between hemoglobin level
and left ventricular mass index in 118 nondiabetic pa-
tients with CKD while Levin et al [36] noted that patients
with CKD had a 32% increase of left ventricular mass
index for each half-gram decrease in hemoglobin. It is
not unreasonable to suggest that similar increases in left
ventricular mass index might be observed among individ-
uals with chronic anemia in the absence of CKD, increas-
ing the risk of decompensated heart failure and death.
A number of limitations to our observations should
be noted. We were unable to control for risk factors
outside of the scope of the data abstraction. For example,
we lack of information regarding care postdischarge and
it is possible that differences in posthospital medication
use or intensity of follow-up may have influenced sur-
vival. Further, there are pertinent variables with many
missing values, such as albumin and ejection fraction,
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that are related to the presence and severity of athero-
sclerotic CVD and of the underlying heart failure. There
is also lack of transfusion information and it is possible
that some patients were transfused because of their low
hematocrit. While these factors may have influenced
postdischarge risk of death, there is no reason to suspect
that postdischarge care or missing information would
differ by degree of reduction in hematocrit and thus the
effect on our results is likely to be a conservative bias
toward the null. Finally, it is possible that the degree of
CKD may be misclassified [37]. While we accounted for
this possibility by examining the sensitivity of our results
to specification of renal function using both predicted
creatinine clearance and serum creatinine, it is possible
that laboratory-to-laboratory variations in creatinine
measurement may have occurred [38].
What is the clinical relevance of these observations?
Clinicians need to be aware that hospitalized patients
with acute myocardial infarction have increased preva-
lence of CKD and that their care should reflect recom-
mendations from current clinical practice guidelines spe-
cifically targeted at preservation of renal function [39].
These recommendations include strict blood pressure
control, preferential use of ACE inhibitors, and restric-
tion of dietary protein to USDA recommended daily
allowance of 0.8 g/kg/day [40, 41].
Anemia should be identified in CKD patients with
ischemic heart disease, evaluated and, in iron-replete
individuals without other causes for decreased hemoglo-
bin, erythropoietin therapy should be initiated with a
target goal between 11 g/dL and 12 g/dL. Clinicians
should recognize that, based on current evidence, partial
correction of renal related anemia should improve qual-
ity of life, cognitive status, exercise tolerance, and func-
tional status in patients with CKD. Increasing the hemo-
globin to current recommended levels has been found
to be safe and not related to increased rate of loss of
renal function. In contrast, evidence to support either a
beneficial effect of correction of anemia in CKD patients
with or without comorbid CVD on survival or risk of
progression to ESRD is lacking.
CONCLUSION
We found a high prevalence of both decreased hema-
tocrit and CKD among elderly patients discharged alive
from the hospital following an acute myocardial in-
farction. Both anemia and CKD were independent pre-
dictors of death during follow-up. Our observations pro-
vide additional support for the design of clinical trials
that would address the role of anemia correction in the
management of patients with CVD with and without
concomitant CKD.
Reprint requests to William McClellan, M.D., M.P.H., Georgia Medi-
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